category,datetime,headline,id,image,related,source,summary,url
company,1768836660,3 “Forever Stocks” to Hold When the Market Won’t Sit Still,138187454,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"Chevron, Colgate-Palmolive, and Merck highlight how dividends, durable businesses, and long-term growth drivers can support a buy-and-hold investment strategy",https://finnhub.io/api/news?id=3b3e95d23d25fd53b61c2a12d84ff5a6bdff14918a1dbc8fbf41b7fdfe571858
company,1768832220,CytomX Stock Rises 31% in a Month: Here's What You Should Know,138177976,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.,https://finnhub.io/api/news?id=c9f2832a6ce58830b0db1e61a3f0309cacc0c0d92b6c5b9e4e66351971909b84
company,1768827900,Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform,138177032,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"PALO ALTO, Calif., January 19, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform.",https://finnhub.io/api/news?id=9294e0f3dd9f057589016f59c0e3ae00d5e696e39db9ce2fe3acf267cf616109
company,1768826280,Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan,138177946,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.,https://finnhub.io/api/news?id=503f4b6fbb9bb2db559370a3732a67ffc25763a4cff27963a2a84b662fa84d15
company,1768810273,Is Merck (MRK) Pricing Reflect Long Term Value After Recent Share Price Strength,138175743,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"If you are wondering whether Merck's current share price reflects its true worth, this article walks through what the numbers are really saying about the stock. Merck's shares last closed at US$108.83, with a 7.7% return over the past 30 days and 15.3% over the last year, while the 7 day return was a 0.3% decline and the year to date return sits at 2.2%. The 3 year and 5 year returns are 8.5% and 64.8% respectively. Recent attention on Merck has been shaped by ongoing product developments...",https://finnhub.io/api/news?id=226f52f8ab2852b7818a64e6e3c53c3038943440e395ed37f503aa81547c7fad
company,1768797336,3 Profitable Stocks to Consider Right Now,138179028,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRK,Yahoo,"Profitable companies tend to be more resilient, giving them the flexibility to invest and return capital to shareholders. Businesses that consistently generate earnings can better navigate downturns and capitalize on new opportunities.",https://finnhub.io/api/news?id=918a7a3ea2d3a745b81f2b0bb656dfb1db0202670922e96130d5e6291c02e115
